Health care stocks were lower late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each shedding about 0.9%.
The iShares Biotechnology ETF (IBB) eased 0.2%.
In corporate news, enGene (ENGN) shares fell past 7% after UBS downgraded the stock to neutral from buy and cut its price target to $7 from $34.
Moderna (MRNA) reported a Q4 loss of $2.91 per share, worse than the $2.83 loss expected in a FactSet poll. Revenue was $966 million, better than the consensus estimate of $942.8 million. Its shares gained about 4%.
OS Therapies (OSTX) shares jumped 12%. The firm said it signed agreements for the commercial-ready manufacturing of OST-HER2 to support anticipated Biologics Licensing Authorization filing.
West Pharmaceutical Services (WST) shares popped past 7%. Deutsche upgraded the stock to buy from hold while lowering its price target to $250 from $275.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。